WATERLOO, Belgium--(BUSINESS WIRE)--Advanced Medical Diagnostics SA/NV (AMD), a privately held company that has developed HistoScanning™, today announced the publication of the final results from the open phase of the prospective, multi-centre and pan-European clinical study (PHS-021), evaluating the Prostate HistoScanning™ application. HistoScanning™ is the award winning Tissue Characterisation modality that utilises raw ultrasound data. HistoScanning™ provides additional and meaningful information for better management of cancer patients by providing visual reassurance for decision making.
